Year-end Sale % OFF 
Abstract
Gliclazide, a sulphonylurea derivative possessing an “in vivo” hypoglycaemic action, inhibits “in vitro” platelet release induced by thrombin or collagen. It does not alter 14CO 2 production from [6- 14C] glucose, but opposes its increase by thrombin. It is an activator of adenylate cyclase increasing the level of [ 3H] cyclic AMP formed within the intact platelets from [ 3H] adenine or [ 3H] adenosine. Finally, it inhibits the effects of thrombin and collagen on platelet adenylate cyclase activity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
